National Human Genome Research Institute
BETHESDA, Md., Tues., Jan. 19, 2010 — An international research consortium has found 13 new genetic variants that influence blood glucose regulation, insulin resistance, and the function of insulin-secreting beta cells in populations of European descent. Five of the newly discovered variants increase the risk of developing type 2 diabetes, the most common form of diabetes.
The results of two studies, conducted by the Meta-Analyses of Glucose and Insulin Related Traits Consortium (MAGIC), provide important clues about the role of beta cells in the development of type 2 diabetes. The studies, funded in part by the National Institutes of Health, appear online Jan. 17, 2010, in Nature Genetics.
"The findings from these ambitious, large-scale studies represent an enormous achievement in international cooperation involving hundreds of researchers and many thousands of individuals who contributed genetic samples for the study. The results give us exciting new directions for future research in the biology of type 2 diabetes, which poses a major and growing public health problem worldwide," said NIH Director Francis S. Collins, M.D., Ph.D., an author of both papers.
In one paper, the MAGIC investigators set out to find genes that influence metabolic traits, including fasting glucose and insulin levels and measures of beta cell function and insulin resistance. About 2.5 million genetic variants were analyzed in 21 genome-wide association studies (GWAS) that had enrolled 46,186 individuals who did not have diabetes and had been tested for measures of glucose and insulin regulation. GWAS look for common genetic associations by scanning the DNA of thousands of individuals. The huge numbers of genetic samples boosts the chances of finding subtle associations of genetic variants with specific diseases or traits. The most common variation is a change in a single nucleotide polymorphism (SNP), or single base pair change, in one of the building blocks of DNA.
The initial analysis yielded 25 candidate SNPs that were further tested in genetic samples from about 77,000 additional individuals. This step led to 16 SNPs that were clearly associated with fasting glucose and beta cell function and two SNPs associated with fasting insulin and insulin resistance. The investigators then asked whether any of the SNPs raise type 2 diabetes risk by comparing gene variants from thousands of people with and without type 2 diabetes.
Among the five variants that raise type 2 diabetes risk, one of the more intriguing SNPs is in the region of ADCY5, which influences fasting and postprandial glucose levels. Another is in FADS1, which is linked with fasting glucose as well as lipid traits. None of the variants found in the MAGIC studies were associated with type 1 diabetes, an autoimmune disease that has been traced mainly to genes that regulate immune function.
"The hallmarks of type 2 diabetes are insulin resistance and impaired beta cell function. We were intrigued to find that most of the newly found variants influence insulin secretion rather than insulin resistance. Only one variant, near IGF1, is associated with insulin resistance," said lead author Inês Barroso, Ph.D., of the Wellcome Trust Sanger Institute, Cambridge, England.
Beta cell impairment may play a larger role in type 2 diabetes than previously recognized, the authors suggest. Also, the environment may contribute to insulin resistance more than it does to insulin secretion. Learning how the genes influence cell signaling and development, glucose sensing, and hormonal regulation will assist the development of targeted methods to prevent and treat diabetes, they conclude.
"Our study shows that genetic studies of glycemic traits can identify loci for type 2 diabetes risk," says lead co-author Jose Florez, M.D., Ph.D., of Massachusetts General Hospital and Harvard Medical School. "However, not all loci that influence blood glucose regulation are associated with greater risk for type 2 diabetes. Some loci elevate fasting glucose slightly but do not raise diabetes risk. It appears that it's not the mere elevation in glucose, but how glucose is raised, that determines type 2 diabetes risk."
In the second paper, MAGIC researchers evaluated genetic associations with glucose levels 2 hours after an oral glucose challenge in a subset of 15,234 participants. They found that a genetic variant in the gene GIPR, which codes for the receptor of gastric inhibitory polypeptide, a beta cell regulating hormone, influences blood glucose levels after a glucose challenge, or sugary meal. Individuals with the risk variant have reduced beta cell function.
The discovery highlights the role of incretin hormones, which are released from endocrine cells in the gut. "This finding adds to a growing body of evidence implicating the incretin pathways in type 2 diabetes risk. These pathways, which stimulate insulin secretion in response to digestion of food, may offer a potential avenue for therapeutic intervention," said senior author Richard Watanabe, Ph.D., of the University of Southern California.
The variants were found in populations of European descent, but the researchers expect that some will have similar effects in other populations. Future research will attempt to answer that question. "Even with the discovery of these variants, we've only explained about 10 percent of the genetic contribution to fasting glucose in people who do not have diabetes," Florez cautioned. Yet undiscovered genes may be found by studies that increase sample sizes to detect smaller effects and look for less common variants as well as non-SNP variants-for example, insertions, deletions, and duplications of DNA that haven't been well studied yet.
About 24 million people in the United States have diabetes. Worldwide, about 285 million people have the disease, according to the International Diabetes Federation. Diabetes is the main cause of kidney failure, limb amputations, and new onset blindness in adults and is a major cause of heart disease and stroke. Type 2 diabetes, which accounts for up to 95 percent of all diabetes cases, becomes more common with increasing age. It is strongly associated with obesity, inactivity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, and racial or ethnic background. The prevalence of diagnosed diabetes has more than doubled in the last 30 years, due in large part to the upsurge in obesity. For more information about diabetes, visit http://diabetes.niddk.nih.gov/index.htm.
The MAGIC studies required extensive collaboration by many researchers on both sides of the Atlantic.* The consortium found the genes and replicated the findings by analyzing genetic samples from up to 122,743 individuals who took part in 54 different studies funded by many publicly and privately funded sources in Europe, Australia, Canada, and the United States. Ten of these studies** were funded by components of the NIH, including the National Institute on Aging, the National Institute of Diabetes and Digestive and Kidney Diseases, the National Heart, Lung, and Blood Institute, the National Human Genome Research Institute, and the National Center for Research Resources. One study, the National Health and Nutrition Examination Survey, is conducted by the National Center for Health Statistics, a part of the Centers for Disease Control and Prevention.
The National Institutes of Health (NIH) - The Nation's Medical Research Agency - includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. It is the primary federal agency for conducting and supporting basic, clinical and translational medical research, and it investigates the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.
* Corresponding authors of the first paper, in addition to Drs. Barroso and Florez, include Mark I. McCarthy, M.D., of the University of Oxford and Michael Boehnke, Ph.D., of the University of Michigan. Equally contributing first authors are Josée Dupuis, Ph.D., of Boston University; Claudia Langenberg, Ph.D., of the University of Cambridge; Inga Prokopenko, Ph.D., of the University of Oxford; Richa Saxena, Ph.D., of the Broad Institute; and Nicole Soranzo, Ph.D., of Wellcome Trust Sanger Institute.
Corresponding authors of the second paper, in addition to Dr. Watanabe, include James Meigs, M.D., MPH, of Harvard and MGH; Nick Wareham, M.D., of the University of Cambridge; and Leif Groop, M.D., Ph.D., of Lund University in Malmö, Sweden. Dr. Saxena and Marie-France Hivert, M.D., of Harvard and MGH are joint first authors.
** The Amish Research Studies, Atherosclerosis Risk in Communities Study, Baltimore Longitudinal Study of Aging, Cardiovascular Health Study, Family Heart Study, Framingham Heart Study, FUSION Study, InChIANTI Study, SardiNIA Study, and the Whitehall II Study.
Top of page
Last Reviewed: February 28, 2012